Power Law company profile

Seagen

Biotech & Life Sciences · Bothell, United States · Founded 1998 · IPO 2001 Decacorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$42B

Market cap · 2026

Revenue

$2.30B

Latest reported FY

Investors

5 investors on Seagen's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

Sofinnova Investments

Indosuez Ventures

OVP Venture Partners

Series B+ 2 investors entered at this stage

International Biotechnology Trust

Scale Venture Partners

Global footprint

Where Seagen has talent and traffic

AI talent share

0.5% of workforce is AI talent
(4 of 761 staff)

Core AI00%

Other AI40.53%

Non-AI workforce75799.47%

Patent intelligence

$403M patent portfolio · 218 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$403M

0.96% of market cap · 3.1× the top peer Loxo Oncology ($130M)

218 active patent families

Where Seagen innovates CarcinosisCancer researchAntiendomysial antibodiesMolecular biologyPharmaceutical drug

Tech-focus vs peers

Where Seagen concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Seagen and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Seagen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo